Cencora agrees to USD 2.4 billion deal as Cencora stock costs EUR 296.75

Published on 10/26/2026 at 11:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cencora raises fiscal 2026 adjusted EPS floor to USD 17.90 after its oncology deal. Cencora stock costs EUR 296.75 on October 26, 2026.

Acquisition and earnings outlook

Cencora agreed to a USD 2.4 billion oncology deal on October 21, 2026.
Cencora raised its fiscal 2026 adjusted earnings per share floor to USD 17.90.
Cencora stock trades at EUR 296.75 at 11:34 a.m. CET at Lang & Schwarz on October 26, 2026.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora (ISIN US03073E1055) was trading at EUR 296.75 at Lang & Schwarz on October 26, 2026 at 11:34 a.m. CET. The pharmaceutical distributor had signed a USD 2.4 billion agreement to acquire American Oncology Network on October 21, 2026, according to Cencora.

Deal expands oncology platform

The transaction values American Oncology Network at an enterprise value of USD 2.4 billion. The package includes USD 2.3 billion at closing and contingent value rights of up to USD 100 million, while Cencora expects to pay USD 1.7 billion for a 75 percent stake if eligible shareholders retain 25 percent through an equity rollover.

American Oncology Network has more than 350 oncology providers across 21 states. Cencora already owns 4 percent of the network, and the agreement remains subject to regulatory clearances and shareholder approval, details also reported by Reuters.

What does the deal mean for earnings?

Cencora expects the acquisition to add to adjusted diluted earnings per share in the second year after closing. The company also raised its fiscal 2026 adjusted earnings per share floor to USD 17.90, placing it at the high end of its previous USD 17.75 to USD 17.95 range, according to the October 21 release.

Three milestones since August

On August 5, 2026, Cencora reported adjusted earnings per share of USD 4.48 for its fiscal third quarter, versus a USD 4.35 consensus estimate, while revenue reached USD 84.75 billion, according to MarketBeat. On October 8, 2026, management lifted fiscal 2026 adjusted earnings per share guidance to USD 17.75 to USD 17.95 from USD 17.70 to USD 17.90, as reported in the Benzinga transcript. The October 21 oncology agreement is the third milestone.

Next results arrive November 4

Cencora plans to release fiscal fourth-quarter results before the New York Stock Exchange opens on November 4, 2026, with a conference call at 8:30 a.m. ET, according to Cencora.

Stock price and valuation context

Cencora's primary listing is on the NYSE, where the stock was last quoted at USD 331.00 on October 23, 2026 at 4:00 p.m. ET. Its market capitalization was USD 63.2 billion, and the 52-week range was USD 244.82 to USD 377.54 on that date. The euro quotation places the German investor's reference in a separate currency from the NYSE figures.

Cencora was trading at EUR 296.75 at Lang & Schwarz on October 26, 2026 at 11:34 a.m. CET. The further course of trading is shown by the continuously updated real-time quote of Cencora stock.